# Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

> **NCT00710528** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 192 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Lymphoma, Non-Hodgkin (NHL)
- Acute Myeloid Leukemia (AML)
- Multiple Myeloma (MM)

## Interventions

- **DRUG:** CAL-101

## Key facts

- **NCT ID:** NCT00710528
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-12
- **Final completion:** 2012-08
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2012-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00710528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00710528, "Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00710528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*